Dr Salman Tamaddon-Jahromi
Advanced Research Assistant
Salman is the Neurodegeneration Experimental Lead at the Open Targets Validation Lab, working to generate experimental evidence towards identifying new routes to therapeutic intervention in Alzheimer’s and Parkinson’s diseases.
Salman specialises in the application of iPSC-derived neuronal models and advanced CRISPR-Cas9 techniques to generate scientifically rigorous experimental evidence for the validation or invalidation of identified targets from genome-wide CRISPR-Cas9 screens.
By collaborating closely with academic and industrial partners, he has successfully established a customised framework for large-scale systematic target validation. This framework encompasses the establishment of orthogonal complementary workflows, implementation of quality and performance controls, and development of disease-relevant phenotypic assays related to autophagy & lysosomal dysfunction, protein aggregation, and synaptic homeostasis disruption.
His extensive research experience includes prior involvement in translational studies at Swansea University. During this time, he focused on investigating wound healing using pulsed-electromagnetism and evaluating the therapeutic effects of novel lytic peptide drugs on pancreatic ductal adenocarcinoma organoid models.